Teceleukin
Also known as: Aldesleukin, Proleukin, recombinant IL-2 (Roche), Recombinant IL‑2, rIL-2 (teceleukin), Ro 23-6019, ro-23-6019, Teceleukin
Source Teceleukin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Teceleukin (recombinant interleukin‑2) is a cytokine‑based immunotherapy approved for prescription use. It is administered intravenously or subcutaneously to stimulate the immune system against certain malignancies, most notably metastatic renal cell carcinoma and melanoma. Clinical investigations have also explored its role in combination regimens and adoptive cell therapies for advanced cancers such as neuroblastoma.
Mechanism of Action
Teceleukin binds to the high‑affinity interleukin‑2 receptor (IL‑2R) on T‑lymphocytes, natural‑killer (NK) cells, and lymphokine‑activated killer cells. This interaction triggers intracellular signaling that drives proliferation, activation, and differentiation of these immune subsets, and initiates a cytokine cascade involving interferons and tumor‑necrosis factor. The amplified cytotoxic cell populations can recognize and destroy tumor cells, providing the antitumor effect of IL‑2 therapy.
What the Research Shows
Early reviews described IL‑2 as a pleiotropic immune modulator that expands T, B, NK, and LAK cells, with dose‑related toxicities requiring intensive monitoring. A 1991 phase II trial combined continuous‑infusion Teceleukin with interferon in renal cell carcinoma, reporting two complete and two partial remissions among fifteen patients. Subsequent pilot and phase I/II studies (2007, 2011) used Teceleukin to support adoptive transfer of autologous γδ T cells in advanced renal cell carcinoma; these trials noted fever, fatigue, hepatic enzyme rises, and grade ≥ 3 events (often linked to concurrent zoledronic acid), but also observed tumor‑doubling‑time prolongation and occasional complete responses. A 2021 neuroblastoma protocol incorporated Teceleukin with cytokine support, reporting manageable toxicities and feasibility. Across studies, objective response rates in metastatic renal cell carcinoma average around 20%, with complete responses in roughly 5% of patients, though results vary with dosing and combination strategies.
Reported Benefits
Clinical data indicate that Teceleukin can induce objective tumor responses in metastatic renal cell carcinoma, with complete remissions reported in a minority of patients and durable responses lasting over a year in some cases. When combined with interferon or used to support adoptive γδ T‑cell therapy, it may enhance tumor‑doubling‑time and achieve additional complete or stable disease outcomes. The cytokine also facilitates immune activation that can be leveraged in multi‑agent regimens for other cancers such as melanoma and neuroblastoma.
Limitations of the Evidence
Evidence is largely confined to small, non‑randomised trials focusing on renal cell carcinoma; response rates are modest and heterogeneous. Severe, dose‑related toxicities limit tolerability and require intensive monitoring, constraining broader use. Optimal dosing schedules, the benefit of combination versus monotherapy, and efficacy in cancers beyond RCC and melanoma remain uncertain, highlighting the need for larger controlled studies.
Safety Considerations
Teceleukin is associated with dose‑dependent adverse effects including hypotension, capillary leak leading to edema, renal dysfunction, fever, fatigue, and elevated liver enzymes. High‑dose intravenous regimens can provoke cardiovascular, pulmonary, hematologic, neurological, endocrine, and dermatologic complications, often necessitating dose interruptions. Grade ≥ 3 toxicities were common when IL‑2 was co‑administered with zoledronic acid, though most events were reversible with supportive care. Monitoring in a critical‑care setting is recommended.
How It Is Administered
Teceleukin is supplied as a recombinant protein for intravenous infusion or subcutaneous injection. Clinical protocols have employed continuous intravenous infusion over several days, intermittent bolus dosing, or subcutaneous schedules, often as part of combination regimens with interferon, zoledronic acid, or adoptive cell transfers. Formulations are sterile solutions intended for use under medical supervision.
Routes of Administration
Goals & Uses
- NK cell and T cell expansionImmunologyModerate
- Metastatic melanomaOncologyHigh
- Metastatic renal cell carcinomaOncologyHigh
- HIV/AIDS immune reconstitutionInfectious Disease / ImmunologyLow
- Antitumor immunotherapyOncologyLow
Contraindications
- Organ transplant recipientsImmunologyHigh
- Severe hypersensitivity to IL‑2AllergyHigh
- Active uncontrolled infectionInfectious DiseaseModerate
- Autoimmune disease (active)ImmunologicalHigh
- Organ transplant recipients on immunosuppressionTransplantHigh
- Severe cardiac dysfunctionCardiovascularHigh
Adverse Effects
- Capillary leak syndromeVascularCommonLeakage of fluid from blood vessels into tissues
- ThrombocytopeniaHematologicUncommonLow platelet count
- HypotensionCardiovascularCommonLow blood pressure
- Neurotoxicity / mental status changesNeurologicalUncommon
- Nausea/vomitingGastrointestinalCommon
- Renal dysfunctionRenalUncommon
- Fever and chillsConstitutionalCommon
- Fever/chillsConstitutionalCommon
- Nausea and vomitingGastrointestinalCommon
Drug Interactions
- High‑dose corticosteroidsModerate
- Antihypertensive agentsModerate
- CyclosporineModerate
- Nephrotoxic agentsModerate
- CorticosteroidsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveRelative
- BreastfeedingReproductiveRelative
- Patients with renal or hepatic impairmentOrgan FunctionRelative
Regulatory Status
- European UnionApprovedApproved: metastatic renal cell carcinoma, metastatic melanomaApproved under similar trade names
- JPApprovedApproved: renal cell carcinoma, melanomaMarketed as Teceleukin
- United StatesApprovedApproved: metastatic renal cell carcinoma, metastatic melanomaMarketed as Aldesleukin (Proleukin)
- United KingdomUnapprovedNo regulatory approval in the UK.
Approved in the US (as aldesleukin/Proleukin) in 1992; marketed as Teceleukin in Japan and other regions.
Evidence & Sources
- Journal ArticleModerateKintzel PE, Calis KA1991-01-01T00:00:00.000000Z
- Journal ArticleModerateKobayashi H, et al.2007-01-01T00:00:00.000000Z
- Journal ArticleModerateMittelman A, et al.1991-01-01T00:00:00.000000Z
- Journal ArticleModerateKobayashi H, et al.2011-01-01T00:00:00.000000Z
- Journal ArticleModerateHara J, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateWhittington R, Faulds D1993-01-01T00:00:00.000000Z
Frequently Asked Questions
What types of cancer have been treated with Teceleukin?
Most clinical experience involves metastatic renal cell carcinoma and melanoma. Smaller studies have examined its use in neuroblastoma and as an adjunct to adoptive γδ T‑cell therapy for advanced renal cell carcinoma.
Why is intensive monitoring required during treatment?
High‑dose IL‑2 can cause severe, reversible toxicities such as hypotension, capillary leak, and organ dysfunction. Continuous hemodynamic and laboratory monitoring in a critical‑care environment helps manage these risks promptly.
Can Teceleukin be given alone, or must it be combined with other agents?
Both approaches have been studied. Monotherapy can produce objective responses, but combination regimens with interferon, zoledronic acid, or adoptive cell therapy have shown additional activity, though they may also increase toxicity.
Is Teceleukin approved for use in all cancers?
Regulatory approval is limited to specific indications, chiefly metastatic renal cell carcinoma. Use in other malignancies is investigational and based on clinical trial protocols.
What are the most common side effects patients experience?
Patients typically report fever, fatigue, nausea, and transient elevations in liver enzymes. More serious effects include hypotension, edema, and renal dysfunction, especially at higher intravenous doses.
What is Teceleukin?
Teceleukin (recombinant interleukin‑2) is a cytokine‑based immunotherapy approved for prescription use. It is administered intravenously or subcutaneously to stimulate the immune system against certain malignancies, most notably metastatic renal cell carcinoma and melanoma. Clinical investigations have also explored its role in combination regimens and adoptive cell therapies for advanced cancers such as neuroblastoma.
What is Teceleukin used for?
Teceleukin is educationally associated with: NK cell and T cell expansion, Metastatic melanoma, Metastatic renal cell carcinoma, HIV/AIDS immune reconstitution, Antitumor immunotherapy. Educational only — not medical advice.
How is Teceleukin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Teceleukin?
Reported adverse effects include: Capillary leak syndrome, Thrombocytopenia, Hypotension, Neurotoxicity / mental status changes, Nausea/vomiting, Renal dysfunction, Fever and chills, Fever/chills, Nausea and vomiting. This list is not exhaustive — consult a qualified clinician.
Who should avoid Teceleukin?
Recorded contraindications: Organ transplant recipients, Severe hypersensitivity to IL‑2, Active uncontrolled infection, Autoimmune disease (active), Organ transplant recipients on immunosuppression, Severe cardiac dysfunction. Consult a qualified clinician before use.